

Causality between Peripheral Immune Cell Counts and Membranous Nephropathy: A Bidirectional Mendelian Randomization Study

1 **Zhihang Su¹, Liu Wen^{1†}, Xiangning Feng^{2†}, Qijun Wan^{1*}**

2 ¹ Department of Nephrology, Shenzhen Second People's Hospital, the First Affiliated Hospital of
3 Shenzhen University, Shenzhen, China

4 ² NMPA Key Laboratory for Quality Monitoring and Evaluation of Vaccines and Biological
5 Products, One Health Center of Excellence for Research and Training, School of Public Health, Sun
6 Yat-Sen University, Guangzhou 510080, PR China

7 *** Correspondence:**

8 Corresponding Author: Qijun Wan (Email: qiyuan2224@sina.com)

9

10 **Keywords:** Membranous nephropathy, Immune cell, Peripheral blood cell, Mendelian
11 randomization, Genome-wide association studies (GWAS).

12

13 **Abstract**

14 **Background:**

15 Membranous nephropathy (MN), an autoimmune disease, has not yet been fully elucidated regarding
16 its relationship with immune cells.

17 **Methods:**

18 As a primary method in this Mendelian randomization (MR) analysis, we employed the Inverse
19 Variance Weighted (IVW), Wald Ratio (WR), Steiger filtering, Weighted Median, Weighted
20 mode, MR-Egger, Mendelian randomization pleiotropy residual sum, and outlier (MR-PRESSO) and
21 Leave-one-out sensitivity test. Reverse MR analysis was utilized to investigate whether MN affects
22 immune cells.

23 **Results :**

24 After False Discovery Rate multiple correction (threshold was 10%), it was determined that
25 CD45RA⁺ CD8⁺ T cell (IVW OR=1.074, 95%CI: 1.034-1.114, P=0.0001, P^{FDR}=0.036), Effector
26 Memory CD8⁺ T cell (IVW OR=0.929, 95%CI: 0.895-0.964, P=0.0001, P^{FDR}=0.036), HLA DR⁺
27 CD8⁺ T cell (IVW OR=0.921, 95%CI: 0.884-0.960, P=0.0001, P^{FDR}=0.036) are significantly affected
28 by MN. CD28⁺ CD45RA⁻ CD8⁺ T cell (WR OR=0.513, 95%CI: 0.357-0.793, P=0.0003,
29 P^{FDR}=0.061), CD8 on Terminally Differentiated CD8⁺ T cell (WR OR=0.378, 95%CI: 0.219-0.652,
30 P=0.0005, P^{FDR}=0.061), and HVEM on Effector Memory CD4⁺ T cell (WR OR=0.378, 95%CI:
31 0.219-0.652, P=0.0005, P^{FDR}=0.065), among others, are considered immune cells that possess
32 protective factors against MN. However, HLA DR on CD33⁺ HLA DR⁺ CD14⁻ (WR OR=1.910,
33 95%CI: 1.269-2.876, P=0.002, P^{FDR}=0.065), CD80 on granulocyte (WR OR=2.606, 95%CI:

34 1.417-4.792, $P=0.002$, $P^{\text{FDR}}=0.065$), and CD62L⁺ plasmacytoid Dendritic Cell (WR OR=1.508,
35 95%CI: 1.138-1.998, $P=0.004$, $P^{\text{FDR}}=0.071$) pose a risk to MN. When increased by one standard
36 deviation in peripheral blood, these immune cells positively or negatively impact the risk of MN with
37 an odds ratio (OR).

38 **Conclusions:**

39 The MR analysis unveiled the association between immune cells and MN. We have deepened our
40 understanding of the pathogenic mechanisms linking MN and immune cells and also identified new
41 targets for immunotherapy in MN.

42 **1 Introduction**

43 Membranous nephropathy, an autoimmune disease, is characterized by the formation and deposition
44 of immune complexes on the basement membrane, resulting in the thickening of glomerular capillary
45 walls(van de Logt et al. 2019). This can lead to pathological and physiological disruptions of the
46 podocyte structure, resulting in proteinuria. Some patients with membranous nephropathy experience
47 mild symptoms. At the same time, severe cases may present with decreased serum albumin levels
48 and generalized edema, known as nephrotic syndrome, and can progress to end-stage kidney disease.
49 Approximately 80% of patients with membranous nephropathy (primary membranous nephropathy)
50 have no identifiable cause(Couser 2017). In contrast, the remaining cases, known as secondary
51 membranous nephropathy (SMN), are connected with other conditions such as lupus erythematosus,
52 hepatitis B virus infection, and malignant growths. The main target antigens for primary membranous
53 nephropathy are PLA2R, THSD7A, NELL1, SEMA3B, and PCDH7(Sethi 2021). While
54 antigen-specific T cells and B cells have not yet been characterized in primary membranous
55 nephropathy (PMN), autoantibodies targeting these antigens have been identified(Chung et al. 2022).
56 Two-sample Mendelian randomization (MR) employs instrumental variables (IVs), which are proxy
57 variables representing genetic variations, to simulate the causal impact of exposure on
58 outcomes(Sekula et al. 2016). Typically, single nucleotide polymorphisms (SNPs) identified in
59 genome-wide association studies (GWAS) are employed as genetic instruments to estimate the causal
60 effect of exposure on outcomes(Sekula et al. 2016). Simultaneously, we aim to minimize the impact
61 of confounding factors and reverse effects. Unlike traditional observational research, MR can
62 mitigate the impact of confounding factors(Georgakis and Gill 2021). Previous studies have shown a
63 correlation between membranous nephropathy and inflammation and the immune response(Ronco et
64 al. 2021). Nevertheless, there is a lack of research analyzing the specific cell subpopulations
65 associated with MN. Our study aims to establish the identity of the specific cell subpopulations
66 connected with MN. The study design is depicted in Figure 1. Initially, we will employ MR using
67 data from the Blood Cell Consortium(BCX) meta-analysis(Vuckovic et al. 2020), Peripheral Immune
68 Cell GWAS summary statistics by Orr et al.(Orrù et al. 2020), and membranous nephropathy GWAS
69 data from the Kiryluk Lab to identify the specific cell subpopulations associated with MN(Xie et al.
70 2020).

71 **2 Methods and materials**

72 **2.1 Data of exposure**

73 The effect estimates of single nucleotide polymorphisms (SNPs) linked to peripheral blood cell
74 counts, such as total leukocytes, lymphocytes, monocytes, neutrophils, eosinophils, and basophils,
75 are obtained from the meta-analysis conducted by the Blood Cell Consortium (BCX), comprising
76 data from 563,085 individuals of European descent(Vuckovic et al. 2020).

77 To analyze lymphocyte subpopulations, which encompass T cells [naïve, central memory (CM),
78 effector memory (EM), terminally differentiated (TD), regulatory (Treg), and natural killer (NKT)
79 cells], as well as B cells (naïve, unswitched memory, switched memory, and transitional memory
80 cells), we employed GWAS data obtained from Orr et al. This study examined 3,757 individuals
81 from the Sardinian founder population using flow cytometry(Orrù et al. 2020).

82 **2.2 Data of outcome**

83 We have chosen Idiopathic Membranous Nephropathy (IMN) as the outcome variable. The data was
84 obtained from a Genome-Wide Association Study (GWAS) focused on primary IMN, involving 2150
85 cases and 5829 controls across five European cohorts(Xie et al. 2020). All patients in the database
86 diagnosed with membranous nephropathy were confirmed through kidney biopsy. Furthermore, the
87 database excluded secondary factors such as drugs, malignant tumors, infections, or autoimmune
88 diseases, ensuring the focus on IMN. The study population comprised individuals of European
89 descent.

90 **2.3 Mendelian Randomization**

91 We conducted bidirectional MR to examine the causal connection between MN and peripheral blood
92 cells as well as immune cell subpopulations. In cases where only one instrumental variable was
93 available, we employed the Wald ratio (WR) as the primary method for Mendelian randomization
94 (MR) analysis. In scenarios involving multiple instrumental variables, we utilized the inverse
95 variance weighted (IVW) method as the main approach to estimate causal relationships. Additionally,
96 we employed MR-Egger, Weight median, and Weighted mode as supplementary methods. Given the
97 multiple analyses performed, there exists a potential for obtaining false positive results in Mendelian
98 randomization (MR). We employed the false discovery rate (FDR) methodology for multiple tests to
99 address this concern, setting the threshold at 10%(Van den Eynden et al. 2018; Kang et al. 2010;
100 Bouras et al. 2022).

101 **2.4 Selection of instrumental variables**

102 Correlation: Our objective was to establish the individual associations of instrumental variables (IVs)
103 with peripheral blood cells and lymphocyte subpopulations. We conducted a preliminary screening
104 using a P-value threshold $5e-08$, which confirmed the robust correlation between the instrumental
105 variables and the aforementioned exposures. IVs with $F < 10$ [computed according to the F formula:
106 $F = R^2(n - k - 1) / k(1 - R^2)$, $F' = (\beta/SE)^2$] were excluded to strengthen the association between the
107 instrumental variables and the exposures(Burgess, Thompson, and CRP CHD Genetics Collaboration
108 2011; de Klerk et al. 2023).

109 Independence: To guarantee the independence of variations in the instrumental variables (IVs), we
110 conducted clustering using the linkage disequilibrium (LD) reference panel derived from the 1000
111 Genomes Project(“High-Coverage Whole-Genome Sequencing of the Expanded 1000 Genomes
112 Project Cohort Including 602 Trios - PubMed” n.d.). At each locus, we retained the single nucleotide
113 polymorphism (SNP) with the lowest p-value, excluding any other SNPs within a 10000 kb window
114 with an $R^2 < 0.001$ correlation with the IVs.

115 Exclusion criteria: We eliminated IVs with outcome p-values $< 5e-05$, as they could potentially be
116 associated with MN. This step improved the accuracy of our MR analysis.

117 Confounding factors were identified using phenotype scanning. If a factor was found to influence
118 both the exposure and the outcome simultaneously, it was excluded from subsequent analysis. We
119 will exclude specific phenotypes, such as asthma, inflammatory bowel disease, and systemic lupus
120 erythematosus, that can potentially impact peripheral blood immune cell counts.

121 The analysis encompassed a total of 790 instrumental variables.

122 **2.5 Sensitivity analysis and directional test**

123 After conducting the MR analysis, it is essential to validate the results through sensitivity analysis
124 and directional tests. MR analysis is susceptible to issues such as horizontal pleiotropy,
125 heterogeneity, and reverse causality. We employ the MR-Egger test and Mendelian randomization
126 pleiotropy residual sum and outlier (MR-PRESSO) to evaluate the presence of horizontal pleiotropy
127 in the instrumental variables. In order to examine heterogeneity in the instrumental variables, we
128 utilize the IVW, MR-Egger, and Cochran's Q test. For directional tests, we employ the Steiger
129 filtering test and reverse MR analysis. The Steiger filtering test is employed to ensure the accuracy of
130 the positive direction. In the reverse MR analysis, we interchange the exposure and outcome
131 variables and conduct MR analysis again.

132 **3 Results**

133 Using bidirectional Mendelian randomization, we observed no causal relationship between peripheral
134 blood cell counts, specifically lymphocyte count and MN (Figure 2). Furthermore, we did identify
135 causal relationships between specific lymphocyte subpopulations and MN (Figure 3). In the analysis
136 results of this subgroup, which specifically examined the causal relationship between lymphocyte
137 subpopulations and MN, After False Discovery Rate multiple correction (threshold was 10%), it was
138 determined that CD45RA⁺ CD8⁺ T cell (IVW OR=1.074, 95%CI: 1.034-1.114, P=0.0001,
139 P^{FDR}=0.036), Effector Memory CD8⁺ T cell (IVW OR=0.929, 95%CI: 0.895-0.964, P=0.0001,
140 P^{FDR}=0.036), HLA DR⁺ CD8⁺ T cell (IVW OR=0.921, 95%CI: 0.884-0.960, P=0.0002, P^{FDR}=0.036)
141 are significantly affected by MN. CD28⁺ CD45RA⁻ CD8⁺ T cell (WR OR=0.513, 95%CI:
142 0.357-0.793, P=0.0003, P^{FDR}=0.070), HVEM on naive CD4⁺ T cell (WR OR=0.591, 95%CI:
143 0.420-0.833, P=0.0027, P^{FDR}=0.070), and HVEM on CD8⁺ T cell (WR OR=0.622, 95%CI:
144 0.446-0.868, P=0.005, P^{FDR}=0.082), among others, are considered immune cells that possess
145 protective factors against MN. However, HLA DR on CD33⁺ HLA DR⁺ CD14⁻ (WR OR=1.910,
146 95%CI: 1.269-2.876, P=0.002, P^{FDR}=0.070), CD80 on granulocyte (WR OR=2.606, 95%CI:
147 1.417-4.792, P=0.002, P^{FDR}=0.070), and CD62L⁻ plasmacytoid Dendritic Cell (WR OR=1.508,
148 95%CI: 1.138-1.998, P=0.004, P^{FDR}=0.076) pose a risk to MN. When increased by one standard
149 deviation in peripheral blood, these immune cells have a positive or negative impact on the risk of
150 MN with an odds ratio (OR) as indicated. This suggests that an increase in the counts of specific
151 lymphocyte subpopulations may increase the risk of developing MN. Conversely, MN patients may
152 exhibit elevated counts of certain lymphocyte subpopulations, leading to downstream effects that
153 could be associated with diseases related to these subpopulations. The sensitivity analysis conducted
154 on the aforementioned MR results indicates that horizontal pleiotropy and heterogeneity can be
155 disregarded (p > 0.05).

156 **4 Discussion**

157 Genome-wide association studies (GWAS) have recognized multiple reproducible genetic
158 associations between common single nucleotide polymorphisms (SNPs) and both common
159 autoimmune diseases and immune-mediated disorders(Cotsapas et al. 2011; Gutierrez-Arcelus, Rich,

160 and Raychaudhuri 2016). Some of these associations are observed across multiple phenotypes. From
161 a genetic standpoint, this confirms the interconnectedness of these immune-related diseases. In
162 clinical practice, it is frequently observed that certain cases, like systemic lupus erythematosus, can
163 result in secondary membranous nephropathy(Mok 2009). Similarly, patients with idiopathic
164 membranous nephropathy may concurrently develop autoimmune diseases, including systemic lupus
165 erythematosus and rheumatoid arthritis(Miyazaki et al. 2023; Caza et al. 2021). However, during MR
166 analysis, we treat these phenotypes, which have the potential to cause changes in immune cell counts,
167 as confounding factors. Eliminating these confounding factors prior to analysis can produce more
168 accurate results.

169 Although distinct diseases necessitate varying dosages, there is often an overlap in the
170 utilization of immunosuppressants and hormones for their treatment(Lazar and Kahlenberg 2023;
171 Burmester and Pope 2017). Therefore, it is imperative to comprehend the impact of their respective
172 targets on gene regulation and immune function. Immunophenotypes, including signaling responses,
173 immune cell abundance, and serum cytokine levels, have the potential to determine pivotal immune
174 actions associated with the risk of autoimmune disorders. Consequently, the identification of crucial
175 immunophenotypes and the elucidation of causal relationships between phenotypes have a critical
176 impact on unraveling the mechanisms underlying autoimmune diseases and facilitating the provision
177 of targeted immunotherapies tailored to specific immunophenotypes.

178 MN, classified as an autoimmune disease, exhibits a strong association with immune cells.
179 However, in current research, distinguishing whether specific immunophenotypic changes are
180 compensatory or causal poses a challenge. One of the focal points of our investigation pertains to the
181 difficulty in discerning the abundance of immune cell subsets that exhibit upstream or downstream
182 relationships with MN. In this study, we have undertaken an unprecedented approach by integrating
183 peripheral blood cell count levels with GWAS data of MN for MR analysis. Our MR analysis has
184 revealed causal associations between specific immune cell subsets in peripheral blood and MN.
185 These cells, having established causal relationships, can act as either upstream or downstream factors
186 in the context of membranous nephropathy. By targeting immune cell subsets associated with
187 upstream factors, potential avenues for immunotherapy can be identified, while those linked to
188 downstream factors hold promise for understanding the development of subsequent conditions
189 following membranous nephropathy. B cells, T cells, autoantibodies, cytokines, and complement
190 system activation collectively contribute to the pathogenesis of MN. An imbalance in the regulatory
191 T cell population is recognized as a prominent characteristic among untreated membranous
192 nephropathy patients(Motavalli et al. 2021). T cells can be divided into three categories according to
193 their activation stages: naïve T cells, effector T cells, and memory T cells. MR analysis results
194 suggest that a decrease in the peripheral blood count of specific CD4+ T cell subsets could
195 potentially increase the risk of MN. In related studies, idiopathic membranous nephropathy patients
196 included in the study exhibited peripheral lymphocytes. Although there were no significant
197 differences in the numbers of peripheral lymphocytes, T cells, and B cells between the two groups, an
198 elevated percentage of CD4+ T cells was observed(Kuroki et al. 2005). Our preliminary inference
199 aligns with these findings, even though the CD4+ T cells in our study were not further divided into T
200 cell subsets.

201 Studies employing immune cell infiltration analysis have demonstrated significantly higher
202 numbers of CD4 T cells, CD8 T cells, natural killer (NK) cells, monocytes, and macrophages in the
203 renal tissue of membranous nephropathy patients compared to healthy tissue (P<0.001).

204 Our findings indicate that an increase in the peripheral blood level of CD80 in granulocytes is
205 associated with an elevated risk of developing membranous nephropathy. CD80 plays a role in innate
206 and adaptive immune activation and has been implicated in the pathogenesis of renal disease
207 syndromes. The excessive secretion of cytokines by activated granulocytes can promote
208 inflammation and immune responses, ultimately leading to the deposition of immune complexes in
209 podocytes and resulting in symptoms such as proteinuria.

210 It is worth noting that CD80 (also known as B7-1) is primarily expressed on antigen-presenting
211 cells and acts as a critical co-stimulatory molecule for T cell activation by binding to the T cell
212 surface receptor CTLA-4. A study involving pediatric and adult patients demonstrated elevated
213 urinary CD80 levels in various glomerular diseases, particularly those with a urinary
214 protein/creatinine ratio $\geq 3\text{g/g}$ (“Urinary CD80 Discriminates Among Glomerular Disease Types and
215 Reflects Disease Activity - PubMed” n.d.). Interestingly, even in lupus nephritis patients with high
216 levels of proteinuria, urinary CD80 was found to be elevated. However, our research indicates that
217 urinary CD80 is positively correlated with proteinuria and negatively correlated with serum albumin
218 levels, suggesting its potential as a marker for podocyte injury (Zen et al. 2023).

219 The count of plasmacytoid dendritic cells (pDCs) has also been found to be associated with an
220 increased risk of membranous nephropathy. However, currently, there is a lack of specific research
221 exploring the relationship between membranous nephropathy and dendritic cells.

222 Conventional dendritic cells type 1 (cDC1) represent a subset of dendritic cells that are
223 primarily involved in cross-presentation to CD8 T cells. Several studies have indicated that the
224 number of cDC1 is associated with the severity of various renal conditions, including acute tubular
225 necrosis, the presence of crescents in immune-mediated glomerulonephritis, interstitial fibrosis in
226 IgA nephropathy and lupus nephritis, as well as the prognosis of IgA nephropathy (Chen et al. 2021).
227 In immune-mediated glomerulonephritis, there is a robust correlation between the number of cDC1
228 and crescent formation. The abundance of cDC1 in the periglomerular and intraglomerular regions
229 suggests their potential involvement in crescent formation, which may be relevant to some instances
230 of membranous nephropathy associated with crescent formation.

231 An increase in the count of CD4+ T cells expressing HVEM (Herpesvirus entry mediator) has
232 been shown to be connected to a reduced risk of developing MN. In this context, we would like to
233 introduce the BTLA/HVEM pathway, which is primarily associated with tumor immunity (Yu et al.
234 2019; “BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer -
235 PubMed” n.d.). The BTLA (B and T lymphocyte attenuator) molecule acts as a co-inhibitory receptor
236 that inhibits T cell receptor (TCR) signaling in T lymphocytes by recruiting Shp1 and Shp2, which
237 are phosphatases involved in downregulating signaling pathways. Within this pathway, HVEM
238 serves as the ligand for BTLA and can also bind to other molecules such as LIGHT
239 (lymphotoxin-like, exhibits inducible expression, and competes with HSV glycoprotein D for
240 HVEM) or lymphotoxin-alpha ($\text{LT}\alpha$). These interactions can trigger co-stimulatory signals or bind to
241 CD160, another co-inhibitory receptor, at different binding sites. Additionally, HVEM can bind to
242 the glycoprotein D of Herpes Simplex Virus (HSV).

243 The involvement of the BTLA/HVEM pathway and its relationship with CD4+ T cells expressing
244 HVEM in membranous nephropathy is an area that requires further research and investigation.

245 Please note that the information provided here is a general overview and may not encompass the
246 entire complexity of the BTLA/HVEM pathway or its specific involvement in membranous
247 nephropathy.

248 An increase in the count of CD4+ T cells expressing HVEM can lead to an increase in the
249 availability of the HVEM ligand. This ligand, in turn, can bind to cytokines unrelated to the
250 pathogenesis of membranous nephropathy and exert effects that antagonize the disease process.

251 Furthermore, LT- α (TNF- β) and TNF- α are closely related structurally as homologs(Aggarwal,
252 Moffat, and Harkins 1984; Aggarwal, Eessalu, and Hass 1985). TNF- β belongs to the TNF
253 superfamily and shares similarities with TNF- α regarding its ability to activate apoptosis and
254 inflammatory signaling(Etemadi et al. 2013). Similar to TNF- α , TNF- β signals through the
255 lymphotoxin β receptor (LT β R) and can activate both classical and non-classical NF- κ B signaling
256 pathways. Additionally, an international genetic study on membranous nephropathy has identified
257 two previously unreported loci, NFKB1 and IRF4, that are associated with inflammation
258 pathways(Xie et al. 2020).

259 There have been studies demonstrating the association between TNF- α and membranous
260 nephropathy. Firstly, genetic polymorphisms in the TNF- α gene have been found to be associated
261 with membranous nephropathy(Thibaudin et al. 2007). Secondly, serum levels of TNF- α have been
262 observed to be increased in patients with MN and other kidney diseases(Roca et al. 2021).

263 The MR results indicate that there is no causal association between the peripheral blood count of
264 various CD20-expressing B cell subsets and the risk of developing MN. This finding supports the
265 rationale behind using rituximab (RTX) treatment for MN, as RTX aims to block antibody
266 production by eliminating antibody-producing plasma cells. However, it is essential to note that this
267 treatment approach may face challenges such as drug resistance and varying effectiveness.

268 Research has indicated that patients with membranous nephropathy have significantly higher counts
269 of plasma cells and regulatory B cells compared to disease-free individuals. Additionally, the
270 expansion of PLA2R-specific memory B cells in vitro has been associated with circulating PLA2R
271 antibody titers(Cantarelli et al. 2020). These findings suggest a compensatory response during the
272 progression of the disease.

273 Our study possesses several strengths. It represents an innovative endeavor of considerable
274 importance in elucidating the potential influence of genetic susceptibility on changes in peripheral
275 blood cell and immune cell counts in relation to the risk of MN. This aspect remains unexplored in
276 previous MR studies. Our study employed genetic instrumental variables that exhibit strong
277 associations with the exposure. Moreover, these instrumental variables were chosen to be
278 independent of the exposure, outcome, and relevant confounding factors. To mitigate bias in the MR
279 analysis, we adjusted parameters to fulfill the three key assumptions of instrumental variable
280 selection.

281 However, our study does have certain limitations: In addition to the inherent limitations linked
282 to the requisite assumptions for causal interpretation in MR studies, we did not extensively explore
283 the downstream effects of membranous nephropathy in our research due to the limited advancements
284 in this domain and the unavailability of relevant information. Nonetheless, this underscores a
285 potential avenue for future investigation. Lastly, owing to the limited representation of other
286 ethnicities, the applicability of our study results is restricted to the European population. Future
287 research is required to extend these findings to encompass other ethnic groups.

288 In conclusion, our study has significantly contributed to advancing our comprehension of
289 membranous nephropathy. Nonetheless, addressing the aforementioned limitations and enhancing the
290 generalizability of these findings to diverse populations necessitate further research endeavors.

291 **5 Conclusion**

292 Through MR, we have identified specific immune cell subsets that are associated with membranous
293 nephropathy. These subsets were then analyzed for their upstream and downstream relationships with
294 the disease process. This comprehensive analysis has significantly expanded our understanding of the
295 complex pathophysiology of MN. Furthermore, this new knowledge has opened up potential new
296 avenues for immunotherapy in the treatment of MN.

297 **6 Conflict of Interest**

298 The authors declare that the research was conducted in the absence of any commercial or financial
299 relationships that could be construed as a potential conflict of interest.

300 **7 Funding**

301 Shenzhen Key Medical Discipline Construction Fund (SZXK009).

302 **8 Acknowledgments**

303 This is a short text to acknowledge the contributions of specific colleagues, institutions, or agencies
304 that aided the efforts of the authors.

305 **9 Data Availability Statement**

306 The datasets (analyzed) for this study can be found in the supplementary document. The datasets
307 (generated) for this study can be found in the address as follow:
308 Membranous nephropathy data can be obtained from:
309 <https://gwas.mrcieu.ac.uk/datasets/ebi-a-GCST010005/> . Immune cell data can be obtained from:
310 <https://www.ebi.ac.uk/gwas/publications/32929287> . Peripheral blood cell data can be obtained from:
311 <https://gwas.mrcieu.ac.uk/datasets/ieu-b-29/> , <https://gwas.mrcieu.ac.uk/datasets/ieu-b-30/> ,
312 <https://gwas.mrcieu.ac.uk/datasets/ieu-b-31/> , <https://gwas.mrcieu.ac.uk/datasets/ieu-b-32/> ,
313 <https://gwas.mrcieu.ac.uk/datasets/ieu-b-33/> , <https://gwas.mrcieu.ac.uk/datasets/ieu-b-34/> .

314 **10 References**

- 315 Aggarwal, B. B., T. E. Eessalu, and P. E. Hass. 1985. "Characterization of Receptors for Human
316 Tumour Necrosis Factor and Their Regulation by Gamma-Interferon." *Nature* 318 (6047):
317 665–67. <https://doi.org/10.1038/318665a0>.
- 318 Aggarwal, B. B., B. Moffat, and R. N. Harkins. 1984. "Human Lymphotoxin. Production by a
319 Lymphoblastoid Cell Line, Purification, and Initial Characterization." *The Journal of*
320 *Biological Chemistry* 259 (1): 686–91.
- 321 Bouras, Emmanouil, Ville Karhunen, Dipender Gill, Jian Huang, Philip C. Haycock, Marc J. Gunter,
322 Mattias Johansson, et al. 2022. "Circulating Inflammatory Cytokines and Risk of Five
323 Cancers: A Mendelian Randomization Analysis." *BMC Medicine* 20 (1): 3.
324 <https://doi.org/10.1186/s12916-021-02193-0>.

- 325 “BTLA-HVEM Couple in Health and Diseases: Insights for Immunotherapy in Lung Cancer -
326 PubMed.” n.d. Accessed November 26, 2023. <https://pubmed.ncbi.nlm.nih.gov/34532285/>.
- 327 Burgess, Stephen, Simon G. Thompson, and CRP CHD Genetics Collaboration. 2011. “Avoiding
328 Bias from Weak Instruments in Mendelian Randomization Studies.” *International Journal of*
329 *Epidemiology* 40 (3): 755–64. <https://doi.org/10.1093/ije/dyr036>.
- 330 Burmester, Gerd R., and Janet E. Pope. 2017. “Novel Treatment Strategies in Rheumatoid Arthritis.”
331 *Lancet (London, England)* 389 (10086): 2338–48.
332 [https://doi.org/10.1016/S0140-6736\(17\)31491-5](https://doi.org/10.1016/S0140-6736(17)31491-5).
- 333 Cantarelli, Chiara, Marta Jarque, Andrea Angeletti, Joaquin Manrique, Susan Hartzell, Timothy
334 O’Donnell, Elliot Merritt, et al. 2020. “A Comprehensive Phenotypic and Functional Immune
335 Analysis Unravels Circulating Anti-Phospholipase A2 Receptor Antibody Secreting Cells in
336 Membranous Nephropathy Patients.” *Kidney International Reports* 5 (10): 1764–76.
337 <https://doi.org/10.1016/j.ekir.2020.07.028>.
- 338 Caza, Tiffany N., Samar I. Hassen, Zeljko Dvanajscak, Michael Kuperman, Rick Edmondson,
339 Christian Herzog, Aaron Storey, et al. 2021. “NELL1 Is a Target Antigen in
340 Malignancy-Associated Membranous Nephropathy.” *Kidney International* 99 (4): 967–76.
341 <https://doi.org/10.1016/j.kint.2020.07.039>.
- 342 Chen, Titi, Qi Cao, Ruifeng Wang, Guoping Zheng, Farhana Azmi, Jeffery Wang, Vincent W. Lee,
343 et al. 2021. “Conventional Type 1 Dendritic Cells (cDC1) in Human Kidney Diseases:
344 Clinico-Pathological Correlations.” *Frontiers in Immunology* 12: 635212.
345 <https://doi.org/10.3389/fimmu.2021.635212>.
- 346 Chung, Edmund Y. M., Yuan M. Wang, Karen Keung, Min Hu, Hugh McCarthy, Germaine Wong,
347 Lukas Kairaitis, Bhadrans Bose, David C. H. Harris, and Stephen I. Alexander. 2022.
348 “Membranous Nephropathy: Clearer Pathology and Mechanisms Identify Potential Strategies
349 for Treatment.” *Frontiers in Immunology* 13: 1036249.
350 <https://doi.org/10.3389/fimmu.2022.1036249>.
- 351 Cotsapas, Chris, Benjamin F. Voight, Elizabeth Rossin, Kasper Lage, Benjamin M. Neale, Chris
352 Wallace, Gonçalo R. Abecasis, et al. 2011. “Pervasive Sharing of Genetic Effects in
353 Autoimmune Disease.” *PLoS Genetics* 7 (8): e1002254.
354 <https://doi.org/10.1371/journal.pgen.1002254>.
- 355 Couser, William G. 2017. “Primary Membranous Nephropathy.” *Clinical Journal of the American*
356 *Society of Nephrology: CJASN* 12 (6): 983–97. <https://doi.org/10.2215/CJN.11761116>.
- 357 Etemadi, Nima, Jessica K. Holien, Diep Chau, Grant Dewson, James M. Murphy, Warren S.
358 Alexander, Michael W. Parker, John Silke, and Ueli Nachbur. 2013. “Lymphotoxin α Induces
359 Apoptosis, Necroptosis and Inflammatory Signals with the Same Potency as Tumour Necrosis
360 Factor.” *The FEBS Journal* 280 (21): 5283–97. <https://doi.org/10.1111/febs.12419>.
- 361 Georgakis, Marios K., and Dipender Gill. 2021. “Mendelian Randomization Studies in Stroke:
362 Exploration of Risk Factors and Drug Targets With Human Genetic Data.” *Stroke* 52 (9):
363 2992–3003. <https://doi.org/10.1161/STROKEAHA.120.032617>.
- 364 Gutierrez-Arcelus, Maria, Stephen S. Rich, and Soumya Raychaudhuri. 2016. “Autoimmune
365 Diseases - Connecting Risk Alleles with Molecular Traits of the Immune System.” *Nature*
366 *Reviews. Genetics* 17 (3): 160–74. <https://doi.org/10.1038/nrg.2015.33>.

- 367 “High-Coverage Whole-Genome Sequencing of the Expanded 1000 Genomes Project Cohort
368 Including 602 Trios - PubMed.” n.d. Accessed November 14, 2023.
369 <https://pubmed.ncbi.nlm.nih.gov/36055201/>.
- 370 Kang, Un-Beom, Younghee Ahn, Jong Won Lee, Yong-Hak Kim, Joon Kim, Myeong-Hee Yu,
371 Dong-Young Noh, and Cheolju Lee. 2010. “Differential Profiling of Breast Cancer Plasma
372 Proteome by Isotope-Coded Affinity Tagging Method Reveals Biotinidase as a Breast Cancer
373 Biomarker.” *BMC Cancer* 10 (1): 114. <https://doi.org/10.1186/1471-2407-10-114>.
- 374 Klerk, Juliette A. de, Joline W. J. Beulens, Hailiang Mei, Roel Bijkerk, Anton Jan van Zonneveld,
375 Robert W. Koivula, Petra J. M. Elders, Leen M. ’t Hart, and Roderick C. Slieker. 2023.
376 “Altered Blood Gene Expression in the Obesity-Related Type 2 Diabetes Cluster May Be
377 Causally Involved in Lipid Metabolism: A Mendelian Randomisation Study.” *Diabetologia*
378 66 (6): 1057–70. <https://doi.org/10.1007/s00125-023-05886-8>.
- 379 Kuroki, Aki, Masayuki Iyoda, Takanori Shibata, and Tetsuzo Sugisaki. 2005. “Th2 Cytokines
380 Increase and Stimulate B Cells to Produce IgG4 in Idiopathic Membranous Nephropathy.”
381 *Kidney International* 68 (1): 302–10. <https://doi.org/10.1111/j.1523-1755.2005.00415.x>.
- 382 Lazar, Stephanie, and J. Michelle Kahlenberg. 2023. “Systemic Lupus Erythematosus: New
383 Diagnostic and Therapeutic Approaches.” *Annual Review of Medicine* 74 (January): 339–52.
384 <https://doi.org/10.1146/annurev-med-043021-032611>.
- 385 Logt, Anne-Els van de, Maryline Fresquet, Jack F. Wetzels, and Paul Brenchley. 2019. “The
386 Anti-PLA2R Antibody in Membranous Nephropathy: What We Know and What Remains
387 a Decade after Its Discovery.” *Kidney International* 96 (6): 1292–1302.
388 <https://doi.org/10.1016/j.kint.2019.07.014>.
- 389 Miyazaki, Reina, Hiroyuki Ueda, Ayaka Hayashi, Masahiro Okabe, Ai Katsuma, Akihiro Shimizu,
390 Kensuke Joh, et al. 2023. “Neural Epidermal Growth Factor-Like 1-Positive Membranous
391 Nephropathy With Rheumatoid Arthritis.” *Kidney International Reports* 8 (4): 921–24.
392 <https://doi.org/10.1016/j.ekir.2022.12.026>.
- 393 Mok, Chi Chiu. 2009. “Membranous Nephropathy in Systemic Lupus Erythematosus: A Therapeutic
394 Enigma.” *Nature Reviews. Nephrology* 5 (4): 212–20.
395 <https://doi.org/10.1038/nrneph.2009.14>.
- 396 Motavalli, Roza, Jalal Etemadi, Mohammad Sadegh Soltani-Zangbar, Mohamad-Reza Ardalani,
397 Houman Kahroba, Leila Roshangar, Mohammad Nouri, et al. 2021. “Altered Th17/Treg Ratio
398 as a Possible Mechanism in Pathogenesis of Idiopathic Membranous Nephropathy.” *Cytokine*
399 141 (May): 155452. <https://doi.org/10.1016/j.cyto.2021.155452>.
- 400 Orrù, Valeria, Maristella Steri, Carlo Sidore, Michele Marongiu, Valentina Serra, Stefania Olla,
401 Gabriella Sole, et al. 2020. “Complex Genetic Signatures in Immune Cells Underlie
402 Autoimmunity and Inform Therapy.” *Nature Genetics* 52 (10): 1036–45.
403 <https://doi.org/10.1038/s41588-020-0684-4>.
- 404 Roca, Neus, Cristina Martinez, Elias Jatem, Alvaro Madrid, Mercedes Lopez, and Alfons Segarra.
405 2021. “Activation of the Acute Inflammatory Phase Response in Idiopathic Nephrotic
406 Syndrome: Association with Clinicopathological Phenotypes and with Response to
407 Corticosteroids.” *Clinical Kidney Journal* 14 (4): 1207–15.
408 <https://doi.org/10.1093/ckj/sfaa247>.
- 409 Ronco, Pierre, Laurence Beck, Hanna Debiec, Fernando C. Fervenza, Fan Fan Hou, Vivekanand Jha,
410 Sanjeev Sethi, Allison Tong, Marina Vivarelli, and Jack Wetzels. 2021. “Membranous

- 411 Nephropathy.” *Nature Reviews Disease Primers* 7 (1): 69.
412 <https://doi.org/10.1038/s41572-021-00303-z>.
- 413 Sekula, Peggy, Fabiola Del Greco M, Cristian Pattaro, and Anna Köttgen. 2016. “Mendelian
414 Randomization as an Approach to Assess Causality Using Observational Data.” *Journal of*
415 *the American Society of Nephrology: JASN* 27 (11): 3253–65.
416 <https://doi.org/10.1681/ASN.2016010098>.
- 417 Sethi, Sanjeev. 2021. “New ‘Antigens’ in Membranous Nephropathy.” *Journal of the American*
418 *Society of Nephrology: JASN* 32 (2): 268–78. <https://doi.org/10.1681/ASN.2020071082>.
- 419 Thibaudin, D., L. Thibaudin, P. Berthoux, C. Mariat, J.-P. Filippis, B. Laurent, E. Alamartine, and F.
420 Berthoux. 2007. “TNFA2 and D2 Alleles of the Tumor Necrosis Factor Alpha Gene
421 Polymorphism Are Associated with Onset/Occurrence of Idiopathic Membranous
422 Nephropathy.” *Kidney International* 71 (5): 431–37. <https://doi.org/10.1038/sj.ki.5002054>.
- 423 “Urinary CD80 Discriminates Among Glomerular Disease Types and Reflects Disease Activity -
424 PubMed.” n.d. Accessed November 26, 2023. <https://pubmed.ncbi.nlm.nih.gov/33163723/>.
- 425 Van den Eynden, Jimmy, Ganesh Umapathy, Arghavan Ashouri, Diana Cervantes-Madrid, Joanna
426 Szydzik, Kristina Ruuth, Jan Koster, et al. 2018. “Phosphoproteome and Gene Expression
427 Profiling of ALK Inhibition in Neuroblastoma Cell Lines Reveals Conserved Oncogenic
428 Pathways.” *Science Signaling* 11 (557): eaar5680. <https://doi.org/10.1126/scisignal.aar5680>.
- 429 Vuckovic, Dragana, Erik L. Bao, Parsa Akbari, Caleb A. Lareau, Abdou Mousas, Tao Jiang,
430 Ming-Huei Chen, et al. 2020. “The Polygenic and Monogenic Basis of Blood Traits and
431 Diseases.” *Cell* 182 (5): 1214-1231.e11. <https://doi.org/10.1016/j.cell.2020.08.008>.
- 432 Xie, Jingyuan, Lili Liu, Nikol Mladkova, Yifu Li, Hong Ren, Weiming Wang, Zhao Cui, et al. 2020.
433 “The Genetic Architecture of Membranous Nephropathy and Its Potential to Improve
434 Non-Invasive Diagnosis.” *Nature Communications* 11 (1): 1600.
435 <https://doi.org/10.1038/s41467-020-15383-w>.
- 436 Yu, Xueping, Yijuan Zheng, Richeng Mao, Zhijun Su, and Jiming Zhang. 2019. “BTLA/HVEM
437 Signaling: Milestones in Research and Role in Chronic Hepatitis B Virus Infection.”
438 *Frontiers in Immunology* 10: 617. <https://doi.org/10.3389/fimmu.2019.00617>.
- 439 Zen, Renata de Cássia, Wagner Vasques Dominguez, Ivone Braga, Luciene Machado Dos Reis,
440 Lectícia Barbosa Jorge, Luis Yu, Viktoria Woronik, and Cristiane Bitencourt Dias. 2023.
441 “Urinary CD80 and Serum suPAR as Biomarkers of Glomerular Disease among Adults in
442 Brazil.” *Diagnostics (Basel, Switzerland)* 13 (2): 203.
443 <https://doi.org/10.3390/diagnostics13020203>.

444

445

446

447

448

449

450 Figure legends:

451 Figure 1:

452 Flowchart for the Mendelian randomization analysis exploring effects of blood cell counts on
453 membranous nephropathy. SNP, single nucleotide polymorphism; Leu, leukocyte; Lym, lymphocyte;
454 Mono, monocyte; Neutro, neutrophil; Eosino, Eosinophil; Baso, basophil; IVW, Inverse variance
455 weighted; MR-PRESSO, Mendelian Randomization Pleiotropy RESidual Sum and Outlier.

456 Figure 2:

457 Mendelian randomization results of the association between blood cell counts and risk of
458 membranous nephropathy. OR, odds ratio; CI, confidence interval.

459 Figure 3:

460 Mendelian randomization results of the association between immune cell counts and risk of
461 membranous nephropathy. WR, Wald ratio; IVW, Inverse variance weighted; OR, odds ratio; CI,
462 confidence interval; MN, membranous nephropathy; FDR, false discovery rate.

463

464

Exposure	Outcome	No.of.SNP	Method		OR(95% CI)	P	P_FDR
CD28+ CD45RA- CD8+ T cell	MN	1	WR		0.51 (0.36 to 0.74)	0.000	0.070
HVEM on T cell	MN	1	WR		0.63 (0.47 to 0.86)	0.003	0.070
HVEM on Effector Memory CD8+ T cell	MN	1	WR		0.63 (0.47 to 0.86)	0.003	0.070
HVEM on CD4+ T cell	MN	1	WR		0.64 (0.48 to 0.86)	0.003	0.070
HVEM on Central Memory CD4+ T cell	MN	1	WR		0.63 (0.47 to 0.86)	0.003	0.070
HVEM on naive CD4+ T cell	MN	1	WR		0.59 (0.42 to 0.83)	0.003	0.070
HVEM on Effector Memory CD4+ T cell	MN	1	WR		0.63 (0.48 to 0.85)	0.002	0.070
HVEM on CD45RA- CD4+ T cell	MN	1	WR		0.65 (0.49 to 0.87)	0.003	0.070
HVEM on Central Memory CD8+ T cell	MN	1	WR		0.66 (0.50 to 0.87)	0.003	0.070
CD80 on granulocyte	MN	1	WR		2.61 (1.42 to 4.79)	0.002	0.070
HLA DR on CD33+ HLA DR+ CD14-	MN	1	WR		1.61 (1.17 to 2.21)	0.003	0.070
CD62L- plasmacytoid Dendritic Cell	MN	1	WR		1.51 (1.14 to 2.00)	0.004	0.076
HVEM on Terminally Differentiated CD4+ T cell	MN	1	WR		0.60 (0.42 to 0.86)	0.005	0.082
HVEM on CD8+ T cell	MN	1	WR		0.62 (0.45 to 0.87)	0.005	0.082
MN	CD45RA+ CD8+ T cell	4	IVW		1.07 (1.03 to 1.11)	0.000	0.036
MN	Effector Memory CD8+ T cell	4	IVW		0.93 (0.90 to 0.96)	0.000	0.036
MN	HLA DR+ CD8+ T cell	4	IVW		0.92 (0.88 to 0.96)	0.000	0.036

Exposure	Outcome	No.of.SNP	Method	OR(95% CI)	P
Membranous nephropathy	basophil cell count	2	Inverse variance weighted	1.00 (1.00 to 1.01)	0.253
Membranous nephropathy	monocyte cell count	2	Inverse variance weighted	1.00 (0.99 to 1.01)	0.888
Membranous nephropathy	eosinophil cell count	2	Inverse variance weighted	1.00 (0.99 to 1.00)	0.415
Membranous nephropathy	white blood cell count	1	Wald ratio	1.00 (0.99 to 1.02)	0.625
Membranous nephropathy	lymphocyte cell count	1	Wald ratio	1.01 (0.99 to 1.02)	0.362
Membranous nephropathy	neutrophil cell count	1	Wald ratio	1.00 (0.99 to 1.02)	0.596
basophil cell count	Membranous nephropathy	81	Inverse variance weighted	0.75 (0.47 to 1.18)	0.212
			MR Egger	0.40 (0.14 to 1.12)	0.085
			Weighted median	0.77 (0.39 to 1.52)	0.446
			Weighted mode	0.94 (0.22 to 4.03)	0.933
eosinophil cell count	Membranous nephropathy	192	Inverse variance weighted	1.01 (0.79 to 1.27)	0.965
			MR Egger	1.01 (0.64 to 1.59)	0.960
			Weighted median	1.03 (0.68 to 1.55)	0.892
			Weighted mode	1.38 (0.75 to 2.55)	0.305
lymphocyte cell count	Membranous nephropathy	224	Inverse variance weighted	1.00 (0.78 to 1.28)	0.986
			MR Egger	1.06 (0.62 to 1.83)	0.821
			Weighted median	0.95 (0.63 to 1.43)	0.817
			Weighted mode	0.97 (0.53 to 1.78)	0.930
monocyte cell count	Membranous nephropathy	233	Inverse variance weighted	0.98 (0.81 to 1.20)	0.878
			MR Egger	0.90 (0.64 to 1.27)	0.552
			Weighted median	0.93 (0.69 to 1.27)	0.651
			Weighted mode	0.92 (0.66 to 1.30)	0.643
neutrophil cell count	Membranous nephropathy	182	Inverse variance weighted	0.82 (0.62 to 1.09)	0.173
			MR Egger	0.49 (0.27 to 0.91)	0.026
			Weighted median	0.79 (0.51 to 1.22)	0.285
			Weighted mode	0.69 (0.36 to 1.31)	0.255
white blood cell count	Membranous nephropathy	217	Inverse variance weighted	0.80 (0.62 to 1.05)	0.106
			MR Egger	0.58 (0.33 to 1.04)	0.068
			Weighted median	0.80 (0.53 to 1.22)	0.308
			Weighted mode	0.93 (0.45 to 1.93)	0.844



